Sechat - Notícias sobre a cannabis medicinal e cânhamo industrial

Cannabis-based product deliveries are reaching the most remote places in Brazil, revealing the strength of a growing market

Public consultation allows society to give opinions on the agency's priorities for the next two years; preliminary list does not include cannabis

Regulatory advances expand access to cannabis treatments for animals, but veterinarians still face barriers in prescribing and regulating products

In Deusa Cast, a lawyer explains how Customs and Criminal Law act in preventing risks in the importation of cannabis-based products, ensuring safety and agility for companies in the sector

Document developed by a group with 31 Brazilian academic and research institutions points out regulatory barriers and suggests an agile framework to strengthen the scientific and technological sector

Social Affairs Committee confirms Safatle, Cerqueira, and Cardoso's names, in a moment of important reforms at the agency

Social Affairs Committee to analyze four names for leadership positions in health agencies

Anvisa authorizations for importing cannabidiol in São Paulo increased by 6.2% between January and July 2025, consolidating the state as a leader in requests and reflecting the expanded access through the SUS

Understand the step-by-step process to acquire plant derivatives for medicinal purposes

The event brings together experts, companies, and authorities to discuss regulatory advances, research, and innovation in cannabis-based therapies, connecting the entire public and private sector

Debates on medicinal cannabis continue deeply at Cannabis Connection 2025 in November and at the Brazilian Medicinal Cannabis Congress in May 2026, both in São Paulo.

COFFITO Ruling No. 735/2024 authorizes physical therapists with specific training to prescribe medications and supplies; however, Anvisa recognizes only doctors and dentists as prescribers of cannabis for medicinal purposes

Learn How to Access Cannabis Products Through the Unified Health System and Understand the Obligations of Health Insurance Providers

According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and greater medical adherence

On Deusa Cast, lawyer Larissa Meneghel details how the five-year deadline set forth in RDC-327 for clinical cannabis research works and comments on the renewal proposal under review by Anvisa

With the revision of RDC 327/2019, compounding pharmacies gain space in the discussion on medicinal cannabis

Pharmaceutical company Ephar has obtained registration for its Cannabidiol in two concentrations, 50 mg/mL and 100 mg/mL, which will be marketed in a low THC content drop solution

Curitiba welcomes its first exclusive medicinal cannabis pharmacy, in a market that grew from R$ 38.5 million in 2022 to R$ 237.8 million in 2025, while Paraná accounts for only 2.4% of sales, indicating great potential in the state with 11 million inhabitants

Cannten's extract with 71.33 mg/mL expands medicinal treatment options in the country and receives authorization for commercialization

Endogen's extract expands the portfolio of options for medicinal treatments and already has sanitary authorization for commercialization